Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen.
暂无分享,去创建一个
M. Papotti | L. Dogliotti | M. Motta | M. Tampellini | F. Vignani | M. Tucci | A. Berruti | G. Vellani | L. Russo
[1] B. Escudier,et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] M. Papotti,et al. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. , 2007, The Journal of urology.
[3] P. Thall,et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. A. Sant'agnese,et al. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] P. di Sant'Agnese,et al. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] T. H. van der Kwast,et al. Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. , 1999, The American journal of pathology.